Q2 EPS Forecast for Axsome Therapeutics Lifted by Analyst

Key Points

• Zacks Research has raised their Q2 2026 EPS estimate for Axsome Therapeutics from ($0.39) to ($0.31), indicating improved expectations for the company's financial performance.
• Despite the positive revisions, Weiss Ratings maintains a "sell" rating on the stock, while two analysts have given it a Strong Buy rating and fourteen a Buy rating.
• CEO Herriot Tabuteau recently sold 12,774 shares at an average price of $118.84, reflecting a significant 63.86% decrease in their ownership position.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at Zacks Research raised their Q2 2026 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, October 13th. Zacks Research analyst Team now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($0.39). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics' Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($1.41) EPS, Q1 2027 earnings at $0.60 EPS, Q2 2027 earnings at $0.90 EPS, Q3 2027 earnings at $0.93 EPS and FY2027 earnings at $3.34 EPS.

Several other research analysts have also commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 5th. Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a research note on Thursday, July 3rd. They set an "overweight" rating and a $190.00 price objective for the company. Bank of America boosted their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Finally, B. Riley initiated coverage on shares of Axsome Therapeutics in a research note on Wednesday, October 1st. They set a "buy" rating and a $179.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $177.93.

Axsome Therapeutics Trading Up 2.0%

NASDAQ:AXSM opened at $123.52 on Wednesday. Axsome Therapeutics has a one year low of $75.56 and a one year high of $139.13. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. The firm has a market cap of $6.16 billion, a P/E ratio of -24.36 and a beta of 0.52. The firm has a 50-day simple moving average of $117.53 and a 200-day simple moving average of $109.96.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The business had revenue of $150.04 million during the quarter, compared to analyst estimates of $140.02 million.

Institutional Trading of Axsome Therapeutics

Several large investors have recently made changes to their positions in AXSM. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $25,000. Quantbot Technologies LP purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $31,000. AlphaQuest LLC purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $38,000. Neo Ivy Capital Management purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Axsome Therapeutics in the 1st quarter valued at $47,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Axsome Therapeutics

In other news, CEO Herriot Tabuteau sold 12,774 shares of the company's stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $118.84, for a total value of $1,518,062.16. Following the sale, the chief executive officer directly owned 7,229 shares of the company's stock, valued at $859,094.36. This represents a 63.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark E. Saad sold 9,127 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $125.07, for a total transaction of $1,141,513.89. Following the completion of the sale, the director directly owned 10,002 shares in the company, valued at $1,250,950.14. This trade represents a 47.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 243,332 shares of company stock worth $28,824,746 in the last quarter. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.